Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Significant Drop in Short Interest

Posted by on Jul 3rd, 2026

Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totaling 23,029 shares, a drop of 37.5% from the May 31st total of 36,835 shares. Based on an average daily volume of 76,196 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.4% of the shares of the stock are short sold.

Analyst Ratings Changes

NEUP has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. HC Wainwright cut Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $21.00.

View Our Latest Analysis on NEUP

Institutional Investors Weigh In On Neuphoria Therapeutics

Large investors have recently modified their holdings of the company. Commonwealth Equity Services LLC purchased a new position in Neuphoria Therapeutics during the 4th quarter worth $43,000. XTX Topco Ltd purchased a new stake in shares of Neuphoria Therapeutics in the fourth quarter valued at about $47,000. Persistent Asset Partners Ltd raised its holdings in shares of Neuphoria Therapeutics by 173.1% in the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after buying an additional 8,495 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth about $54,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth about $57,000. 15.90% of the stock is owned by institutional investors and hedge funds.

Neuphoria Therapeutics Price Performance

Shares of Neuphoria Therapeutics stock remained flat at $3.38 during trading hours on Friday. 118,687 shares of the stock were exchanged, compared to its average volume of 104,003. The firm has a 50-day moving average price of $4.81 and a two-hundred day moving average price of $4.43. The stock has a market capitalization of $18.27 million, a P/E ratio of -0.31 and a beta of 0.74. Neuphoria Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.47. As a group, research analysts anticipate that Neuphoria Therapeutics will post -4.07 EPS for the current fiscal year.

About Neuphoria Therapeutics

(Get Free Report)

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Read More

Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.